Target intelligence / Profile preview

U1 small nuclear ribonucleoprotein (U1 snRNP)

Target
U1 snRNP
Molecular classification
Small nuclear ribonucleoprotein, snRNP, Spliceosomal complex, Ribonucleoprotein particle
01

Overview

U1 small nuclear ribonucleoprotein (U1 snRNP) is a multi-subunit ribonucleoprotein complex involved in the recognition of the 5’ splice site at the exon-intron junction of precursor mRNA (pre-mRNA). It consists of U1 small nuclear RNA (164 bases), seven common Sm proteins (SmB/B', SmD1, SmD2, SmD3, SmE, SmF, SmG), and three U1-specific proteins (U1-70K, U1-A, U1-C). U1 snRNP binds to the 5’ splice site through base pairing between U1 snRNA and the pre-mRNA, thereby initiating spliceosome assembly. Its structure features a Sm protein ring core, with RNA stem-loops interacting with specific proteins. U1 snRNP is critical not only for canonical splicing but also plays roles in alternative polyadenylation regulation. Beyond its molecular functions, U1 snRNP has clinical relevance as an autoantigen in certain systemic autoimmune diseases, detected by specific autoantibodies[1][2][3][4][5][6][7][8].

Other names
U1 snRNPU1 spliceosomal RNPU1 particleU1 small nuclear RNP
02

Mechanism of action

When targeted experimentally, actions include blocking U1 snRNA—leading to inhibition of spliceosome assembly or altered splicing site usage (e.g., antisense oligonucleotides cause alternative polyadenylation and shorter transcripts)

03

Biological functions

Recognition of the 5'-splice site in pre-mRNAInitiation of spliceosome assemblyFacilitates excision of introns during RNA splicingAlternative polyadenylation regulation
04

Disease associations

Autoantigen in systemic lupus erythematosus (SLE)Autoantigen in mixed connective tissue disease (MCTD)Other (no strong direct disease role beyond autoimmunity)
05

Safety considerations

Direct modulation of U1 snRNP risks affecting global mRNA processing, potentially leading to mis-splicing and broad transcriptomic dysregulationAs an autoantigen, there is an established risk of triggering/maintaining autoimmune responses
06

Interacting drugs

antisense oligonucleotides

1 more in the full profile.

07

Biomarkers

U1 snRNP autoantibodies (anti-U1 snRNP, anti-U1-70K, anti-U1-A) in SLE/MCTD are used as biomarkers for diagnosis and classification

Beyond the preview

Go deeper on U1 small nuclear ribonucleoprotein (U1 snRNP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on U1 small nuclear ribonucleoprotein (U1 snRNP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call